Saint Petersburg

The trials here

What the 98 trials at this site are about, from their registry records.

Conditions

• Lung cancer31 trials
• Metastatic breast cancer12 trials
• Bladder cancer6 trials
• Asthma5 trials
• Chronic lymphocytic leukaemia4 trials
• Liver and biliary tract cancer4 trials
• Ovarian cancer4 trials
• Prostate cancer4 trials
• Amyloidosis3 trials
• Chronic kidney disease3 trials
• COPD3 trials
• Endometrial cancer3 trials
• and 22 more

Phase

• Phase 354 trials
• Phase 212 trials
• Phase 14 trials
• Phase 42 trials
• Phase 1/21 trial
• Phase 2/31 trial

Status

• Active, not recruiting57 trials
• Completed28 trials
• Recruiting5 trials
• Terminated5 trials
• Not yet recruiting2 trials
• Suspended1 trial

Lead sponsor

• AstraZeneca87 trials
• Acerta Pharma BV4 trials
• Checkpoint Therapeutics, Inc.2 trials
• Alcea1 trial
• Alexion Pharmaceuticals, Inc.1 trial
• and 3 more

Running trials

• Recruiting

  Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia

  NCT07247279· AstraZeneca· Source

• Recruiting

  Clinical Study to Compare Efficacy and Safety of Indinol Forto® 200 mg Capsules and Visanne 2 mg Tablets in Treatment of Endometriosis

  NCT07164183· Phase 3· Alcea· Source

  Contact: Kirill Sokolov, MD

• Active, not recruiting

  A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2

  NCT07143604· Phase 2· AstraZeneca· Source

• Recruiting

  Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration

  NCT07052578· AstraZeneca· Source

• Recruiting

  TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation

  NCT07038928· AstraZeneca· Source

• Recruiting

  An Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Treatment Approaches in Russian Federation

  NCT07041606· AstraZeneca· Source

• Recruiting

  Clinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsia

  NCT07088991· AstraZeneca· Source

• Active, not recruiting

  A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria

  NCT06942910· Phase 2· AstraZeneca· Source

• Active, not recruiting

  A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)

  NCT06943833· Phase 2· AstraZeneca· Source

• Active, not recruiting

  A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)

  NCT06606847· Phase 2· AstraZeneca· Source

• Active, not recruiting

  Clinical& Demographic Profiles of patIents With unControllEd Asthma in Russia: Multi-center oBsErvational ReGistry Study

  NCT06521229· AstraZeneca· Source

• Recruiting

  Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)

  NCT06472310· AstraZeneca· Source

• Active, not recruiting

  Treatment and Biomarker Testing Patterns,Treatment Outcomes in a/m NSCLC With and Without Actionable Genomic Alterations

  NCT06245837· AstraZeneca· Source

• Active, not recruiting

  A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy

  NCT05941897· Phase 2· AstraZeneca· Source

• Active, not recruiting

  CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in Russia

  NCT05887011· AstraZeneca· Source

• Active, not recruiting

  A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia

  NCT05456867· AstraZeneca· Source

• Active, not recruiting

  A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

  NCT05120349· Phase 3· AstraZeneca· Source

• Active, not recruiting

  D9319C00001- 1L OC Mono Global RCT

  NCT04884360· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

  NCT04784715· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

  NCT04711252· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

  NCT04538742· Phase 1/2· AstraZeneca· Source

• Active, not recruiting

  A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

  NCT04556773· Phase 1· AstraZeneca· Source

• Active, not recruiting

  A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

  NCT04351555· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

  NCT04512235· Phase 3· Alexion Pharmaceuticals, Inc.· Source

• Active, not recruiting

  Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC

  NCT04550260· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

  NCT04529772· Phase 3· Acerta Pharma BV· Source

• Active, not recruiting

  Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

  NCT04590963· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

  NCT04482309· Phase 2· AstraZeneca· Source

• Active, not recruiting

  Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib

  NCT04421963· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

  NCT04494425· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

  NCT04493853· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

  NCT04379596· Phase 2· AstraZeneca· Source

• Active, not recruiting

  Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

  NCT04269200· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

  NCT04305496· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

  NCT04035486· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

  NCT03997123· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)

  NCT03875235· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

  NCT03833154· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

  NCT03836261· Phase 3· Acerta Pharma BV· Source

• Active, not recruiting

  A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

  NCT03819465· Phase 1· AstraZeneca· Source

• Active, not recruiting

  Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

  NCT03775486· Phase 2· AstraZeneca· Source

• Active, not recruiting

  A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

  NCT03800134· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

  NCT03778957· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients

  NCT03706690· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

  NCT03732677· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

  NCT03682068· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

  NCT03521154· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer

  NCT03528694· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)

  NCT03459846· Phase 2· AstraZeneca· Source

• Active, not recruiting

  Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

  NCT03298451· Phase 3· AstraZeneca· Source

Showing 50 of 64.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Asthma1 recruiting
• Bladder cancer1 recruiting
• Endometrial cancer1 recruiting
• Endometriosis1 recruiting
• Myasthenia gravis1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Completed

  A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils

  NCT06897748· Phase 2· AstraZeneca· Source

• Completed

  Study of Patient With Frequent COPD Exacerbations

  NCT07221981· AstraZeneca· Source

• Completed

  Real-world Study Assessing Efficacy of TezepeLumaB in Patients With Severe Asthma Regardless of Phenotype in Russia

  NCT06566885· AstraZeneca· Source

• Completed

  PRospectIve ObseRvatIonal mulTicenter Study of Patients With Arterial hYpertension and CKD in the Population of Russia

  NCT06372431· AstraZeneca· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

  NCT06344104· Phase 3· AstraZeneca· Source

• Completed

  Hereditary Transthyretin Amyloidosis Polyneuropathy in Patients With Carpal Tunnel Syndrome in Russia

  NCT06414746· AstraZeneca· Source

• Completed

  MultIceNtre Non-intERVentional Study for Efficacy,Safety Evaluation of BREZTRI in Pts With COPD in RussiA

  NCT06422676· AstraZeneca· Source

• Completed

  hATTR Polyneuropathy in Russia

  NCT06365593· AstraZeneca· Source

• Completed

  A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma

  NCT06245551· Phase 3· AstraZeneca· Source

• Completed

  The Prevalence Evaluation of Systemic Lupus Erythematosus in Russian Patients With Reproductive Issues (PRISMA)

  NCT06056778· AstraZeneca· Source

• Completed

  A Non-interventional Prospective Study of 1-st Line Treatment Approaches in OVArian Cancer Patients With HRD+ Status in Russian Federation

  NCT05918042· AstraZeneca· Source

• Completed

  HER2(Human Epidermal Growth Factor Receptor 2) -Positive Metastatic Breast Cancer in Russia

  NCT05905939· AstraZeneca· Source

• Completed

  HER2-low Unresectable and/or Metastatic Breast Cancer in Russia

  NCT05913440· AstraZeneca· Source

• Terminated

  Non-interventional Study of Patients With PN NF1 Starting Selumetinib in Russia

  NCT05891847· AstraZeneca· Source

• Terminated

  Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC

  NCT04786964· Phase 3· Checkpoint Therapeutics, Inc.· Source

• Terminated

  A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia

  NCT05056727· Phase 3· AstraZeneca· Source

• Completed

  Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%

  NCT04986202· Phase 2/3· AstraZeneca· Source

• Terminated

  Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

  NCT04847232· Phase 3· AstraZeneca· Source

• Completed

  Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)

  NCT04609904· Phase 3· AstraZeneca· Source

• Completed

  ALICIA (Acalabrutinib in CLL Therapy)

  NCT04746950· AstraZeneca· Source

• Completed

  Heart Failure Patients Registry

  NCT04709263· AstraZeneca· Source

• Completed

  Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.

  NCT04642469· Phase 3· AstraZeneca· Source

• Completed

  Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy

  NCT04249362· Phase 2· AstraZeneca· Source

• Terminated

  A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia

  NCT04109950· Phase 3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• Completed

  Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients

  NCT04008706· Phase 3· AstraZeneca· Source

• Completed

  Durvalumab Long-Term Safety and Efficacy Study

  NCT04078152· Phase 4· AstraZeneca· Source

• Completed

  Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

  NCT03847428· Phase 3· AstraZeneca· Source

• Completed

  Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

  NCT03519971· Phase 3· AstraZeneca· Source

• Completed

  AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

  NCT02296125· Phase 3· AstraZeneca· Source

• Completed

  AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT02151981· Phase 3· AstraZeneca· Source

• Completed

  Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

  NCT02000622· Phase 3· AstraZeneca· Source

• Completed

  A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.

  NCT01602380· Phase 3· AstraZeneca· Source

• Completed

  To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer

  NCT01496313· Phase 4· Sanofi· Source